Preventing and Troubleshooting Manufacturing Deviations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preventing and Troubleshooting Manufacturing Deviations
Industry experts offer their best practices for dealing with deviations. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

Involve senior management

As a general best practice, experts believe that it's important to have management involved in CAPA programs, not just the Quality unit. Involvement of management is crucial for several reasons, explains Parexel's O'Hara:

  • Management is ultimately responsible for how the company responds to risks and the actions taken
  • Management has the authority and responsibility to provide the resources (e.g., financial, staff) to ensure not only that the company produces a product that is safe and effective, but also that the environment in which the product is produced is safe and compliant with trained, knowledgeable staff
  • Management can encourage the engagement of staff and open communication with staff, which aids in ensuring success from the design of a product to a finished product.

"These three factors also encourage staff to anticipate issues, voice their thoughts as to why or how a deviation occurred and to aid in the corrective and preventive actions taken," says O'Hara. "In my opinion, their knowledge and experience of the management team is invaluable in the deviation and CAPA systems processes.

Adds Teva's Welter, "Management is ultimately responsible for the health and effectiveness of the firm's quality system. Having management participate in the CAPA process will ensure that management is aware and can communicate across the organization the issues that the firm is facing and will no doubt be supporting in any upcoming regulatory inspectional activities. It is crucial that ownership and accountability for corrective actions and effectiveness of those corrective actions be solidly with the organization owning the deviation.

References

1. GAO, FDA Could Strengthen Oversight of Imported Food by Improving Enforcement and Seeking Additional Authorities (May 6, 2010), http://www.gao.gov/products/GAO-10-699T.

2. GAO, Improved Monitoring and Development of Performance Measures Needed to Strengthen Oversight of Criminal and Misconduct Investigations (Jan. 2010), http://www.gao.gov/new.items/d10221.pdf.

3. FDA, Enforcement Strategy (Jul. 15, 2010), http://www.fda.gov/downloads/ICECI/EnforcementActions/UCM225183.pdf.

4. GHTF SG3, Quality Management System–Medical Devices–Guidance on Corrective Action and Preventive Action and Related QMS Processes (Nov. 2010), http://www.ghtf.org/documents/sg3/sg3_n18.pdf.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here